126 related articles for article (PubMed ID: 37657193)
1. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Nasioudis D; Fernandez ML; Wong N; Powell DJ; Mills GB; Westin S; Fader AN; Carey MS; Simpkins F
Gynecol Oncol; 2023 Oct; 177():86-94. PubMed ID: 37657193
[TBL] [Abstract][Full Text] [Related]
2. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract][Full Text] [Related]
3. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
[TBL] [Abstract][Full Text] [Related]
4. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC; Dong F
Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic landscape of RAS mutations in gynecologic cancers.
Son J; Zhang Y; Lin H; Mirallas O; Alvarez Ballesteros P; Nardo M; Clark N; Hillman RT; Campbell E; Holla V; Johnson AM; Biter AB; Yuan Y; Cobb LP; Gershenson DM; Jazaeri AA; Lu KH; Soliman PT; Westin SN; Euscher ED; Lawson BC; Yang RK; Meric-Bernstam F; Hong DS
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687597
[TBL] [Abstract][Full Text] [Related]
6. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Martin L; Simpkins F; Giuntoli R
Gynecol Oncol; 2023 Oct; 177():14-19. PubMed ID: 37611378
[TBL] [Abstract][Full Text] [Related]
7. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
8. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.
Rocca A; Braga L; Volpe MC; Maiocchi S; Generali D
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358725
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
[TBL] [Abstract][Full Text] [Related]
10. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
[TBL] [Abstract][Full Text] [Related]
11. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham RN; Vergote I; Banerjee S; Drill E; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Cibula D; Moore KN; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Kristensen G; Clamp A; Farley J; Iyer G; Ray-Coquard I; Monk BJ
Clin Cancer Res; 2023 Oct; 29(20):4068-4075. PubMed ID: 37581616
[TBL] [Abstract][Full Text] [Related]
12. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
14. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
16. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
Mirkovic J; Sholl LM; Garcia E; Lindeman N; MacConaill L; Hirsch M; Dal Cin P; Gorman M; Barletta JA; Nucci MR; McCluggage WG; Howitt BE
Mod Pathol; 2015 Nov; 28(11):1504-14. PubMed ID: 26336887
[TBL] [Abstract][Full Text] [Related]
17. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N; Martínez-Trillos A; Montraveta A; Lopez-Guerra M; Rosich L; Nadeu F; Valero JG; Aymerich M; Magnano L; Rozman M; Matutes E; Delgado J; Baumann T; Gine E; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer AR; Puente XS; López-Otín C; Lopez-Guillermo A; Campo E; Colomer D; Villamor N
Haematologica; 2019 Mar; 104(3):576-586. PubMed ID: 30262568
[TBL] [Abstract][Full Text] [Related]
19. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
